Last reviewed · How we verify
Klebsiella Joint Infection
Approved treatments
- Ceftriaxon · Centre Hospitalier Universitaire Vaudois
- Fortaz · Pai Holdings Pharm
Fortaz works by binding to penicillin-binding proteins on bacterial cell walls, preventing them from forming a strong cell wall and ultimately leading to bacterial cell death. - Fortaz · Pai Holdings Pharm
Bactericidal agent inhibiting bacterial cell wall synthesis with beta-lactamase resistance. - Rocephin · Generic (originally Roche)
- Ceftazidim · Tel-Aviv Sourasky Medical Center
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Klebsiella Joint Infection patent landscape — cliff calendar, originator estates, attackable patents
- Klebsiella Joint Infection treatment landscape brief
- Klebsiella Joint Infection treatment updates RSS
Frequently asked questions about Klebsiella Joint Infection
What drugs treat Klebsiella Joint Infection?
Tracked treatments include Ceftriaxon, Fortaz, Rocephin, Ceftazidim.
What is the treatment for Klebsiella Joint Infection?
Standard treatment for Klebsiella Joint Infection includes Ceftriaxon, Fortaz, Rocephin, Ceftazidim. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Klebsiella Joint Infection patent cliff · Klebsiella Joint Infection CI report
- Treatment: Ceftriaxon · Centre Hospitalier Universitaire Vaudois
- Treatment: Fortaz · Pai Holdings Pharm
- Treatment: Fortaz · Pai Holdings Pharm
- Treatment: Rocephin · Generic (originally Roche)
- Treatment: Ceftazidim · Tel-Aviv Sourasky Medical Center
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing